首页/数据集/CCT3 drives sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

CCT3 drives sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

Name: CCT3 drives sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC
Creator: Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University
Published: 2023-09-21T19:12:01+08:00

integrated proteome resources2026-02-07 收录

肿瘤耐药机制

铁代谢与癌症治疗

数据链接：

https://www.iprox.cn/page/project.html?id=IPX0007177000 数据链接链接失效反馈

官方服务：

资源简介：

CCT3 drives sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

应用场景：

提供机构：

Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University

创建时间：

2023-09-21

肿瘤耐药机制

信号通路靶向治疗

Taxanes are widely used in chemotherapy, but intrinsic and acquired resistance limit the clinical outcomes. Studies showed tumor interaction with suppressive macrophages plays a key role in taxane res

NIAID Data Ecosystem80

Gene expression data from rapamycin resistant and sensitive cell lines

肿瘤耐药机制

miRNA调控

The mammalian target of rapamycin (mTOR) is a central regulator of cell proliferation. Inhibitors of mTOR are being evaluated as anti-tumor agents. Given the emerging role of microRNAs (miRNAs) in tum

NIAID Data Ecosystem70

YAP activation mediates acquired resistance to ALK inhibitor in ALK rearranged non–small cell lung cancer

肿瘤耐药机制

ALK靶向治疗

To investigate a possible candidate for overcoming the acquired resistance to ALK-TKI, we established an in vitro model of acquired resistance to crizotinib (H3122-CR) by exposing EML4-ALK–positive H3

NIAID Data Ecosystem40

AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Homo sapiens

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

CCT3 drives sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

资源简介：

相关数据集